CERTIFICATE

IMPACT FACTOR 2021

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Nonalcoholic fatty liver disease and chronic kidney disease in patients with chronic heart failure

Author: 
Drapkina, O., Zyatenkova, E. and Ivashkin, V.
Subject Area: 
Health Sciences
Abstract: 

Currently, the routine clinical practice does not include the measurement of glomerular filtration rate (GFR) in patients with the absence of risk factors for Chronic Kidney Disease (CKD). However, recent studies have shown that in patients with nonalcoholic fatty liver disease (NAFLD) it is necessary to estimate GFR, even in the absence of classic risk factors for CKD. Early detection of kidney damage in patients with CHF and NAFLD will help to titrate the correct dose of drugs, avoiding chemical overdose. Materials and Methods: The study included 77 patients with CHF. In all patients, the diagnosis of heart failure was confirmed by measuring the quality NT-pro BNP. The severity of the clinical manifestations of heart failure and the functional status of patients were assessed. All patients underwent clinical and biochemical blood tests, ECG, ultrasound of the liver. Size of the heart chambers, wall thickness of the myocardium and epicardial fat were evaluated by the echocardiography. In all patients GFR, CKD-EPI were calculated, staging of CKD was performed, Fatty Liver Index and NAFLD fibrosis score evaluated. Results: More than half (68%) of the patients with CHF had C 2 stage of CKD, 6% of patients had a C1 stage; 13% - C 3a, 9% - C 3b, 4% - C4 stage CKD. The average value of GFR was 65,4 ± 14,4 ml / min / 1.73 m2. Statistical analysis revealed that with the increase of HF functional class stage of CKD also increase (p = 0,0027). The severity of CKD increases with the level of plasma glucose (p = 0.0022). In addition, it was found that the stage of CKD correlate with increase in the size of the right atrium (p = 0.044). In assessing the biological age of the vessel wall with the help of apparatus "Angioscan" it was revealed that the larger stage of CKD, the higher biological age of the vessel wall in patients with chronic heart failure (p = 0.0027). It was also found that the more severe damage to the kidneys in patients with CHF, the higher level of fibrosis marker PIIINP infarction (p = 0.047). According to FLI, 40% of patients are likely to have hepatic steatosis, in 34% of patients the data for the presence of hepatic steatosis is not obtained, 26% of patients took an intermediate value. According to the NFS, 26% of patients had a high likelihood of liver fibrosis, 9% of patients did not have, 65% of patients are in the "gray zone". The analysis of the correlations revealed that with increasing values of NFS reduced GFR increases CKD stage (p = 0.049). Conclusions: Patients with heart failure and concomitant diseases of the liver and kidneys are in need of more intensive treatment with compulsory inclusion of drugs which reduce the process of fibrosis and remodeling of the vascular wall and have protective properties in relation to the liver and kidneys.

PDF file: 

CALL FOR PAPERS

 

ONLINE PAYPAL PAYMENT

IJMCE RECOMMENDATION

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

 

EDITORIAL BOARD

CHUDE NKIRU PATRICIA
Nigeria
Dr. Swamy KRM
India
Dr. Abdul Hannan A.M.S
Saudi Arabia.
Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran